Who is the CEO of Seegene?

According to the DART company overview, Seegene's representative director is 천종윤, 이대훈 각자대표이사 (name as registered in Korean). The company was founded on 2000-09-18.

Where is Seegene listed?

Seegene trades on the Korea Exchange KOSDAQ market under the ticker 096530. Its fiscal year ends in December.

Does Seegene pay a dividend?

Yes. For fiscal 2025, Seegene paid a cash dividend of ₩1,000 per common share, a 4.1% yield as stated in its annual report, with a payout ratio of 95.5%. The prior year's dividend was ₩800.

Does Seegene have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year). These are factual flags, not investment advice.

Which companies are in the same industry as Seegene?

Under the Korean Standard Industrial Classification recorded on DART, Seegene is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and Rokit Healthcare.

Seegene KRX:096530KOSDAQ

씨젠 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h1

Articles, 7 days28

DART filings, 7 days0

Articles tracked46since Sep 11

In Q2 2026, Seegene reported revenue of ₩136bn, up 19.2% year on year, and operating profit of ₩21.6bn. Seegene (씨젠) appeared in 28 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 21 articles.

Filing signals Profit +50% Revenue & profit growth Screener

Seegene quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩136bn	+19.2%	₩21.6bn margin 15.9%	₩26.0bn
Q1 2026	₩129bn	+11.3%	₩23.6bn margin 18.2%	₩34.7bn
Q4 2025 derived	₩131bn	+13.3%	₩6.9bn margin 5.3%	₩5.0bn
Q3 2025	₩114bn	+4.3%	₩9.6bn margin 8.5%	₩14.6bn
Q2 2025	₩114bn	+13.9%	₩3.1bn margin 2.8%	−₩71m
Q1 2025	₩116bn	+29.0%	₩14.8bn margin 12.8%	₩28.9bn
Q4 2024 derived	₩115bn	+14.8%	−₩6.2bn margin −5.4%	−₩44.1bn
Q3 2024	₩109bn	+18.4%	₩5.3bn margin 4.8%	₩1.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Seegene top stories 2 weeks, by number of outlets

1
씨젠, 호흡기서 비호흡기로 매출 구조 변화 중…'매수'-IBK
2 outlets · 3 articlesFirst report Oct 28 07:45 이데일리
2
씨젠, ‘LMCE 2026’서 종합 검사 전략 강조…감염질환별 포트폴리오 공개
2 outlets · 2 articlesFirst report Oct 26 09:59 더바이오
3
씨젠, LMCE 2026서 종합 검사 전략 소개
2 outlets · 2 articlesFirst report Oct 26 11:00 메디포뉴스
4
씨젠의료재단, CQI 경진대회 "검사 품질·업무 효율성 고도화"
2 outlets · 2 articlesFirst report Oct 29 11:26 의협신문
5
씨젠, 비호흡기 성장에 실적 개선… 포트폴리오 다변화·기술 개발 박차
1 outlets · 2 articlesFirst report Oct 21 16:27 이데일리
6
[서치 e종목] 씨젠, 비호흡기 진단시약 고성장에 매출 성장률↑…주가 상승곡선?
1 outlets · 1 articlesFirst report Oct 22 08:20 데일리인베스트

Latest Seegene news Korean headlines

Oct 2911:26
씨젠의료재단, CQI 경진대회 "검사 품질·업무 효율성 고도화"
의협신문
1 more on this story · 1 outlets
- 씨젠의료재단, CQI 경진대회 개최 "검사 품질·업무 효율성 고도화"글로벌경제신문 · Oct 29 20:41
Oct 2911:25

씨젠의료재단 CQI 경진대회…검사실 문서 자동화 사례 대상
간호사신문
Oct 2807:45
씨젠, 호흡기서 비호흡기로 매출 구조 변화 중…'매수'-IBK
이데일리
2 more on this story · 2 outlets
- 씨젠, 호흡기서 비호흡기로 매출 구조 변화 중…'매수'-IBK이데일리증권 · Oct 28 07:45
- 씨젠, 호흡기서 비호흡기로 매출 구조 변화 중…'매수'-IBK이데일리 · Oct 28 07:45
Oct 2807:44

씨젠, 소화기 진단 매출 호흡기 추월 전망…주력사업 재편
메디코파마
Oct 2618:29

씨젠, 국제학술대회서 호흡기 감염 진단 기술 공유…PCR 기반 종합 검사 강조
백세시대
Oct 2617:30

씨젠, 동시감염까지 잡는 호흡기 진단 기술 공개
아주경제
Oct 2617:04

씨젠, LMCE 2026서 종합 검사 전략 강조…신드로믹 PCR 검사로 원인 병원체·동시감염 여부 확인
베타뉴스
Oct 2616:36

씨젠, LMCE 2026 참가…감염질환별 검사 포트폴리오·자동화 시스템 선봬
이투데이
Oct 2614:47

씨젠, LMCE서 동시감염 사례에 종합검사 전략 공개
글로벌경제신문
Oct 2613:46

"여러 병원체 한번에 확인"…씨젠, 호흡기 종합 검사 전략 공유
아시아경제
Oct 2613:42

씨젠, LMCE 2026서 종합 진단 전략 공개…신드로믹 PCR로 동시감염까지
나눔경제뉴스
Oct 2613:37

씨젠, 한 번에 여러 감염 잡는다…종합 분자진단 전략 공개
한스경제
Oct 2612:10

씨젠, LMCE서 진단기술 선봬...호흡기 동시감염 확인
PRESS9
Oct 2611:30

씨젠, 호흡기 감염 동시진단 강조…검사 자동화 전략 소개
중앙이코노미뉴스
Oct 2611:00
씨젠, LMCE 2026서 종합 검사 전략 소개
메디포뉴스
1 more on this story · 1 outlets
- 씨젠, LMCE 2026서 신드로믹 PCR 기반 ‘종합 검사 전략’ 강조헤럴드경제 · Oct 26 14:45
Oct 2610:25

씨젠, 국제학술대회서 차세대 호흡기 진단 기술 선보여
서울경제
Oct 2610:17

"종합검사 전략 중요"…씨젠, 국제학술대회 참가
뉴시스경제
Oct 2610:15

씨젠, 차세대 호흡기 패널로 동시감염 짚어낸다
바이오타임즈
Oct 2609:59
씨젠, ‘LMCE 2026’서 종합 검사 전략 강조…감염질환별 포트폴리오 공개
더바이오
1 more on this story · 1 outlets
- 씨젠, LMCE 2026 참가...종합 검사 전략 강조스마트투데이 · Oct 26 14:22
Oct 2609:49

씨젠, LMCE서 '종합 검사' 전략 공유···동시감염 진단 중요성 부각
녹색경제신문
Oct 2609:41

씨젠, LMCE서 호흡기 감염 동시진단 가능성 제시
메디컬투데이
Oct 2609:32

씨젠, 학술대회서 호흡기 패널 소개…동시감염 진단 가능성 공유
뉴스1
Oct 2609:29

[위클리오늘] 산업일반 소식_씨젠, 오스템임플란트(10.26)
위클리오늘
Oct 2217:01

[어바웃 G] 씨젠, 천경준 매각 땐 특별결의 외부 찬성표 7배 필요
블로터
Oct 2208:20

[서치 e종목] 씨젠, 비호흡기 진단시약 고성장에 매출 성장률↑…주가 상승곡선?
데일리인베스트
Oct 2116:28
씨젠, 비호흡기 성장에 실적 개선… 포트폴리오 다변화·기술 개발 박차
이데일리
1 more on this story · 1 outlets
- 씨젠, 비호흡기 성장에 실적 개선… 포트폴리오 다변화·기술 개발 박차이데일리 · Oct 21 16:27
Oct 1917:00

씨젠 천경준 회장, 보유주식 절반 이상 매각…379억원 규모
PRESS9
Oct 1409:37

씨젠의료재단, ‘고객감동경영대상’ 11연패
의협신문
Oct 1317:38

[BIO톡]시지바이오 ‘페이스템’, 대만 TFDA 품목허가 획득 外 씨젠·샤페론
글로벌경제신문Regulatory approvalShaperon
Oct 1316:32

씨젠의료재단, 세계 첫 '무인 PCR' 구축…초격차 진단 기술
한국경제

Articles per day 2 weeks

119

221

222

2126

428

329

Company profile

CEO: 천종윤, 이대훈 각자대표이사
Industry: Medical supplies
Founded: 2000-09-18
Fiscal year-end: December
Head office: 서울특별시 송파구
Website: seegene.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Seegene dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩1,000	4.1%	95.5%
FY2024	₩800	3.4%	–
FY2023	₩800	3.5%	–

Same industry Medical supplies

All in industry

Company	Latest quarter op. profit	Articles 30d
HLB	−₩22.5bn	310
PharmaResearch	₩66.5bn	129
Rokit Healthcare	−₩13.5bn	77
Jetema	₩2.3bn	26
AbClon	−₩6.3bn	22
SCL Science	₩406m	22
Nibec	₩103m	17
Asta	−₩839m	16

Compare Seegene side by side with these companies

Seegene DART filings

Oct 2110:04

Other 임원ㆍ주요주주특정증권등거래계획보고서
Other
Oct 1915:50

Other 임원ㆍ주요주주특정증권등거래계획보고서
Other
Sep 2816:55

Other 중간(분기)배당락
Other

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Seegene FAQ

Who is the CEO of Seegene?: According to the DART company overview, Seegene's representative director is 천종윤, 이대훈 각자대표이사 (name as registered in Korean). The company was founded on 2000-09-18.
Where is Seegene listed?: Seegene trades on the Korea Exchange KOSDAQ market under the ticker 096530. Its fiscal year ends in December.
What were Seegene's latest quarterly results?: In Q2 2026, Seegene reported revenue of ₩136bn, up 19.2% year on year, and operating profit of ₩21.6bn. Figures come from reports filed on DART.
Does Seegene pay a dividend?: Yes. For fiscal 2025, Seegene paid a cash dividend of ₩1,000 per common share, a 4.1% yield as stated in its annual report, with a payout ratio of 95.5%. The prior year's dividend was ₩800.
Does Seegene have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year). These are factual flags, not investment advice.
Which companies are in the same industry as Seegene?: Under the Korean Standard Industrial Classification recorded on DART, Seegene is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and Rokit Healthcare.